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Abstract
Objective To analyze the current drug-interaction manage-
ment in Swiss community pharmacies, with a particular
focus on electronic systems, and to compare the results with
those expressed by German general practitioners in a recent
survey.
Methods Data were collected with a postal questionnaire
which was randomly sent to 500 out of 833 community
pharmacies in the German part of Switzerland.
Results The response rate was 57.4%, and only 24.7%
pharmacists reported that they were confronted less than
daily with potential drug interactions. Use of computer
software to identify potential drug interactions was wide-
spread in community pharmacies (90.2%), and the software
was the primary source of information (81.2±29.6%). The
quality of the interaction software was judged sensitive
(identifying all dangerous interactions) by 80.5±21.5%, but
specific (identifying only relevant interactions) by only
38.3±32%. Pharmacists declared a low override rate (14%)
of drug interaction alerts, although unjustified alerts were
reported by 60.6±33.1%. In contrast to general practi-
tioners, pharmacists opted less often for information on the
mechanism of the interaction, and more frequently for
details for dose adjustment. Both groups complained about
deficient information on non-interacting alternatives.
Conclusion The information needs of community pharma-
cists differed considerably from general practitioners, and
pharmacists were overwhelmed by inappropriate alerts
because of a lack of specificity of their drug-interaction
systems. Substantial improvement of drug-interaction soft-
ware systems is thus required at least in two important
aspects, the suppression of inappropriate alerts and the
tailoring to the needs of the user.
Keywords Community pharmacist . Drug interaction .
Pharmacotherapy . Information technology
Introduction
Potential drug interactions are highly prevalent, but the
number of adverse drug reactions caused by drug inter-
actions is probably low [1–4]. Reported incidences in
outpatients range from 9.2% to 70.3% for drug interactions
of any severity, and from 1.2% to 23.3% for those
considered of major relevance [5–11]. A German primary-
care study showed that of all observed major or moderate
potential drug interactions only 11.7 % offered no manage-
ment options, and such drug combinations should thus be
avoided [12]. The majority of the potential drug interactions
do not result in clinical manifestations if they are managed
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adequately, e.g. by dose adjustment or a coordinated
sequence of administration [12]. However, given the
frequency of combination treatment, even a low penetrance
of complications caused by drug interactions will substan-
tially impact drug safety. Indeed drug interactions are
responsible for up to 3.8% of hospital admissions [2, 13–15].
In some countries, including Switzerland, community
pharmacies are obliged to keep a medication history of all
dispensed prescription drugs and to check prescriptions, to
prevent the use of unsafe drug regimens including those
caused by potentially interacting drugs. To comply with
these statutory requirements, almost all pharmacies use
computer software systems for the quality assurance of
pharmacotherapy. These systems identify potential drug
interactions, alert the pharmacy team to intervene before
dispensing potentially interacting drugs, and serve as a
drug-interaction information source.
Thus far, only very few epidemiologic studies on the
adverse outcomes of drug interactions have been per-
formed. Therefore, drug-interaction information sources
generally lack data on clinical importance of potential drug
interactions and information on risk factors that contribute
to their adverse outcomes. Indeed, the majority of general
practitioners were dissatisfied with the information on
therapeutic alternatives, severity, mechanism, and dose
adjustment in the drug-interaction information sources they
used [16]. Consequently electronic drug-interaction infor-
mation sources should include management guidelines for
dose adjustment and spacing of administration times, and
should help to avoid contraindicated drug combinations.
Moreover, they should also provide monitoring information
for an early detection of adverse events.
Drug-interaction information is required on different
levels of drug therapy. First, the prescription of drug
combinations should be supported by appropriate informa-
tion technology to maintain high quality standards already
at the point of care. In addition to the support of physicians
in drug selection and dosing, the dispensing pharmacies
should also have access to comprehensive information on
drug interactions, in order to assess combinations pre-
scribed by several independent physicians in charge of a
patient, and also to detect risks arising from combinations
with drugs dispensed without prescription. Obviously,
safety concerns detected in a pharmacy should be resolved
in communication with the treating physician, who ideally
has access to the same knowledge bases. Because pharma-
cists and physicians have different duties in pharmacother-
apy, and also different training, their information needs may
also differ. We therefore aimed to assess how pharmacists
deal with drug interactions in daily practice, which
information sources they use and wish to have, and how
their requirements relate to those expressed by general
practitioners.
Methods
Study population
From the 833 pharmacies in the German speaking part of
Switzerland, a random sample of 500 community pharma-
cies was invited to participate in this cross-sectional survey.
Pharmacies were selected by use of the freeware Research
Randomizer (http://www.randomizer.org/form.htm). No
stratification or any other selection procedures were
applied.
In Switzerland, community pharmacies dispense 68.9%
of all over-the-counter drugs, and 57.2% of all prescription
drugs. The remaining drugs are dispensed by physicians
(27.8%), hospitals (13.9%), and drug stores (1.2%) [17]. If
not limited by regional legislation, physicians are allowed
to store drugs in their practice and dispense drugs to their
patients.
All Swiss community pharmacies have electronic drug
management systems. The knowledge base on drug
interactions integrated in these systems was originally
developed by ABDATA (Eschborn, Germany) [18] to be
used in all Austrian, German, and Swiss community
pharmacies. The knowledge base is adapted by E-mediat
AG (Schönbühl, Switzerland) to the Swiss market and sold
to pharmacy software providers. Furthermore, it is pub-
lished as an integrated part of Pharmavista [19], a drug
information service which is available on the Internet or on
CD-ROM as a subscription-only service for Swiss health
care professionals. Each drug-interaction monograph is
fully referenced and updated on a monthly basis. Potential
drug interactions are classified into “severe” (life-threat /
intoxication / permanent harm), “moderate” (frequent
therapeutic problems / combination can be administered
but close monitoring required), “minor” (increased or
decreased drug effect / only specific subgroups affected),
“negligible” (no or limited clinical effects / generally no
modification of therapy required) and “external specifi-
cations” (only occurring in particular cases / clinical conse-
quences unclear). The majority of electronic drug-interaction
systems used in Swiss community pharmacies can be set up
to flag only potential drug interactions of moderate and/or
high severity. Such alerts can either be “ignored” (over-
ridden); “considered” (deliberate response to the alert), or
in some cases have to be “analysed” more precisely through
consideration of additional parameters (e.g. patient-related
risk factors) and consultation of drug-interaction infor-
mation sources.
Data collection
The questionnaire included 28 items grouped in four
sections. The first part of the questionnaire contained three
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questions to clarify pharmacists’ perceptions of drug
interactions and the preoccupation with this problem in
daily practice. The second part focused on management of
interaction alerts in pharmacy practice, with three questions
on the configuration of the drug-interaction surveillance
software, three questions on the capability of their drug-
interaction surveillance software to be “sensitive” (software
identifies % of cases of dangerous potential drug inter-
actions) and to be “specific” (software identifies % of cases
of really clinically relevant potential drug interactions) and
to flag “false” alerts (e.g. multiple or repeated alerts for
the same patient, the patient was no longer taking the
interacting drug, in % of cases), and four questions on the
actions taken by pharmacy teams after drug-interaction
alerts. A third part contained five questions on the usage
(frequency and type) of drug-interaction information
sources and the pharmacists’ satisfaction with the provided
information. Eight questions in the fourth part addressed the
communication with physicians. Additionally, character-
istics of the pharmacists (gender, professional experience,
working hours, postgraduate education) and their commu-
nity pharmacies (location, profile of customers, and
implementation of quality management system) were
assessed. We used multiple choice questions or visual
analogue scales ranging from “never” (coded as 0%) to
“always” (coded as 100%).
Questions on pharmacists’ perception of the risk arising
from potential drug interactions, the preoccupation with
potential drug interactions in daily practice, the usage
(frequency and type) of drug-interaction information
sources, and their satisfaction with the information provid-
ed were retrieved from a recent structured questionnaire-
based survey among German general practitioners [16].
The study was carried out between June 2005 and
August 2005. The questionnaire was sent together with a
letter explaining the rationale of the study and a pre-
stamped return envelope. Questionnaires had to be filled
in by the pharmacy manager or his substitute. Compre-
hensibility of the questionnaire was evaluated in a pre-
test among ten community pharmacists. To increase the
response rate, responders could win one of five annual
subscriptions to an educational community pharmacy
drug information service (value=40 EUR). Four weeks
later, a reminder was sent together with a second
questionnaire to non-responders of the survey to further
boost response rates [20]. To characterize non-responders,
gender, age, professional experience, configuration of the
drug-interaction surveillance software settings, and reason
for non-response were assessed in a telephone interview
with 50 randomly selected non-responding pharmacy
managers.
All returned questionnaires were processed with the
automated forms processing software Teleform version 7.0
from Cardiff Software Inc., Vista, CA, USA. Automated
forms processing software was validated by Jorgensen et al.
[21] who showed an improved quality of the data while
reducing the processing time. To avoid potential errors, all
numeric and letter recognitions were verified visually on
data sheets and on screen.
Data analysis
Results are expressed as proportions and as means ±
standard deviation (SD) or medians with the 25% to 75%
interquartile range (IQR). Main descriptive results are
expressed as absolute numbers and percentages. Indepen-
dent two-sample comparison of single variables was
analysed using student’s t-test. Chi-square statistics were
used for categorical comparisons. In a multiple logistic
regression analysis, the daily preoccupation with potential
drug interactions or the frequency of using drug-interaction
information sources as dependent variables were dichoto-
mised into “daily” (for each prescription, several times
daily, daily) versus all other categories (once a week, once a
month, less than once a month, never). Covariates were
gender, professional experience, working hours [%], phar-
macy certified for quality management, pharmacy location
in countryside or village, predominantly changing custom-
ers, postgraduate education as community pharmacist, the
pharmacies` software configuration to flag only “severe”
potential drug interactions, and software configuration of
the length of the period a patient’s past medication history
was screened for potential drug interactions. Odds ratios
(OR) are presented with 95% confidence intervals (CI).
Statistical significance was defined as a p-value <0.05. All
statistical analyses were performed using SPSS for Win-
dows version 13.0 (SPSS, Inc, Chicago, IL, USA).
Results
Characteristics of the study sample
Of 500 invited community pharmacies, 57.4% (287)
returned the questionnaire. Most questionnaires (87.1%,
250/287) were filled in by the pharmacy manager. More
than 95% of the questions were answered by all responders.
Characteristics of the responding pharmacists and their
community pharmacies are presented in Table 1. Compar-
ison of responding pharmacy managers with 50 non-
responding pharmacy managers showed no significant
differences with respect to gender (p=0.54), mean age
(p=0.56), professional experience (p=0.47), and the loca-
tion of their community pharmacies (p=0.36). The main
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reasons for non-response were lack of time or interest
(34%) and personal absence during the survey period
(26%).
Perception of the risk arising from drug interactions
and preoccupation with potential drug interactions
For the majority of the responding pharmacists [91% (261/
287)] drug interactions were an important safety hazard in
pharmacotherapy. Of these, 19.5% (51/261) judged the
clinical relevance of drug interactions to be an outstanding
problem, 76.2% (199/261) to be equally important, and
only 4.2% (11) to be subordinate compared with other
safety hazards in pharmacotherapy. Neither a significant
association with gender or postgraduate specialisation in
community pharmacy nor a trend with age, workload, or
years of professional experience was found (p>0.05). The
majority (75.3%; 216/287) of the responding pharmacists
mentioned the fact that they dealt at least daily with
potential drug interactions.
Configuration and perception of the quality of drug
interaction surveillance software
The community pharmacies’ computers were equipped with
pharmacy software from six different providers, and most
of them (90.2%; 259/287) used their software to identify
potential drug interactions. In contrast, 9.8% (28/287) had
inactivated this option in their computer system. Those
pharmacies were less frequently certified with a quality
management system (p=0.032) and felt less frequently
confronted with potential drug interactions (p<0.001). In
18.5% (48/259) of the community pharmacies, the drug
interaction surveillance software was set to flag only
“severe”, in 39.8% (103/259) to flag “severe” and “mod-
erate”, and in 41.7% (108/259) to flag all potential drug
interactions. In pharmacies in which the software was set to
flag only “severe” potential drug interactions, pharma-
cists dealt less frequently with potential drug interactions
(p<0.001). The median length of the period a patient’s past
medication history was screened for potential drug inter-
actions was 120 days (IQR 90–180 days). Pharmacists
estimated the quality of their drug interaction surveillance
software to be “sensitive” in 80.5±21.5%, to be “specific”
in 38.3±32%, and to flag “false” alerts (e.g. multiple or
repeated alerts for the same patient, the patient was no
longer taking the interacting drug) in 60.6±33.1% of drug-
interaction alerts. If the software was set to flag only
“severe” potential drug interactions, pharmacists (n=259)
rated their drug interaction surveillance software to be less
“sensitive” (72.1±27.0% vs 82.6±19.5%; p=0.018) but
more “specific” (54.7±36.7% vs 34.8±29.8%; p=0.002).
When pharmacists estimated that the software produced
“false” alerts in ≥50% (n=169) of alerts, their software was
configured to observe a significantly longer period of the
medication history (170.5±97.8 days vs 133.1±82.3 days;
p=0.007). Multiple logistic regression analysis confirmed
these results: configuration of the pharmacy software to flag
only “severe” potential drug interactions (OR 0.009, 95%
CI 0.003, 0.028; p<0.001), and the configuration of the
length of the period a patient’s past medication history was
screened for potential drug interactions (OR 1.014, 95% CI
1.003, 1.025; p=0.014) were associated with the daily
preoccupation with potential drug interactions, while no
effect was observed with all other defined covariates (see
Methods).
Management of drug interaction alerts by community
pharmacy teams
Written directives for the management of flagged drug-
interaction alerts were available in 18.5% (48/259) of the
community pharmacies, while 78.4% (203/259) reported that
they had only verbal instructions. Pharmacists estimated
that drug-interaction alerts are always “considered” in 86±
18.6% of cases by their pharmacy teams. This proportion
was not higher if the drug-interaction surveillance software
was configured to flag only “severe” potential drug
interactions (p=0.19). Pharmacists estimated that a more
thorough follow-up “analysis” of drug interaction alerts
through consultation of further information sources was
Table 1 Characteristics of the participating pharmacists and their
pharmacies
Characteristics of
responding pharmacists
N* (100%)
Mean age ± SD [years] 283 45.0±9.4
Female gender 286 157 (54.9%)
Mean years of professional
experience ± SD [years]
283 18.5±9.5
Mean working time ± SD 282 90%±15%
Pharmacy manager 284 250 (88.0%)
Postgraduate specialisation
as community pharmacist
285 215 (75.4%)
Characteristics of community
pharmacies
N* (100%)
Location 286
City or urban agglomeration 200 (69.9%)
Countryside or village 86 (30.1%)
Predominantly regular customers
(versus changing customers)
285 212 (74.4%)
Implementation of quality
management system
286
Implemented 27 (9.5%)
Submitted for certification 83 (29.0%)
No quality management system 176 (61.5%)
*Number of 287 pharmacists responding to individual question
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required in 63.8±32.7% of the alerts. This frequency was
higher if the drug interaction surveillance software was
configured to flag only “severe” potential drug interactions
(p<0.001).
Of all community pharmacies, 79.8% (229/287) docu-
mented activities triggered by the detection of potential
drug interactions. Of them, 36.2% (83/229) stated that they
documented their activities only if a “severe” potential drug
interaction was flagged, 20.1% (46/229) only if a physician
was contacted, 30.1% (69/229) only if the therapy was
modified (e.g. closer monitoring, dose adjustment, or
alternative therapy), and 11.8% (27/229) in any situation.
Furthermore, pharmacists estimated that in their pharmacies
70.8±28.1% of the customers are informed about poten-
tially interacting drugs.
Perception of use and quality of drug interaction
information sources
In the case of consultation of drug-interaction information
sources to analyse an alert more precisely or to answer a
specific question, pharmacists indicated that they favoured
drug-interaction information provided by their electronic
drug interaction system in 81.2±29.6%, and the published
national drug formulary [22] in 67.2±32% of the cases.
More male pharmacists reported to use preferentially (i.e. in
≥50% of cases) electronic drug-interaction information
sources (community pharmacies’ drug-interaction surveil-
lance software, the drug interaction knowledge base of
Pharmavista [19], or further specific electronic drug
interaction information sources available via internet or
from their local computer or personal digital assistant
software (e.g. DRUGREAX Thompson Micromedex,
Greenwood Village or Stockley’s Drug Interactions, Elec-
tronic Version 2006 The Pharmaceutical Press, London,
etc.) (p=0.05). In general, 70.3% of the pharmacists (199/
283) reported that they use their drug interaction informa-
tion sources “daily”.
Multiple logistic regression analysis did not show an
association between the “daily” use of drug-interaction
information sources and defined covariates (see methods).
Figures 1 and 2 show satisfaction with the content
provided by the drug-interaction information sources
currently used and the expectations with respect to the
content of future drug-interaction information sources. The
use of the same questions asked in a recent survey in
general practitioners [16] enabled direct comparison of
responses of community pharmacists with those of general
practitioners. Congruently, community pharmacists and
general practitioners were most dissatisfied with the content
of their drug-interaction sources concerning non-interacting
alternative therapies. Both equally considered the severity
Fig. 1 Swiss pharmacists’ and
German general practitioners’
satisfaction with the content
provided by the drug-interaction
information sources they cur-
rently use. Comparison of the
results of two questionnaire sur-
veys in 287 pharmacists and
1216 general practitioners. N =
number of responding pharma-
cists and general practitioners.
P-value: chi-square analysis of
differences between the
responses of pharmacists and
general practitioners who an-
swered that the content provides
insufficient information
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of the outcome to be essential information, but all other
comparisons of pharmacists’ and general practitioners’
satisfaction and future expectations differed significantly
(p<0.001) (Figs. 1 and 2).
Communication between pharmacists and prescribing
physicians concerning potential drug interactions
Pharmacists reported a median of 25 (IQR 10–30) overall
contacts to prescribing physicians, and a median of 3 (IQR
1–6) due to potential drug interactions during the 3 months
preceding the survey. A total of 56.8% (163/287) pharma-
cists reported that they contacted physicians in general
exclusively by telephone, the remaining 43.2% (124/287)
that they did so by telephone or fax, video conferencing,
email, mail, or via the patient. If the contact was induced by
a potential drug interaction, most of the pharmacists
(72.5%, 208/287) chose direct communication by telephone.
Pharmacists’ perception of the frequency of reasons for
contacting a physician is presented in Fig. 3. The majority
of pharmacists (62.7%; 180/282) reported that they con-
tacted physicians “rarely” or “never” as a result of potential
drug interactions. Pharmacists working in pharmacies
whose drug-interaction surveillance software is configured
to flag only “severe” potential drug interactions reported
similar frequencies (72.9%; 35/48) for contacting a physi-
cian “never” or “rarely” compared with the other pharma-
cists (61.2%; 126/208) (p=0.128).
Discussion
The use of computer software for prospective medication
surveillance is a very common approach to avoiding
medication errors [1]. In our study, all community pharma-
cies were equipped with drug-interaction surveillance
software, and most of them (90.2%) used it to identify
potential drug interactions. Electronic drug-interaction
checks in community pharmacies and physicians' offices
can reduce the dispensing of prescriptions with severe
interactions up to 67.5 % [23]. Although immediate impact
on prescription and dispensing has been demonstrated,
there is only limited and inconclusive evidence as to
whether the computer software is effective enough to
prevent medication errors [24–26]. Evaluation of the
performance of pharmacies’ electronic drug-interaction
systems in the USA showed that they largely varied in
their ability in terms of specificity and sensitivity to identify
clinically important potential drug interactions in daily
practice [27].
In our survey, pharmacists reported that they considered
86% of interaction alerts, and thus admit to in fact ignoring
Fig. 2 Swiss pharmacists’ and
German general practitioners’
expectations with respect to the
content of future drug-interac-
tion information sources. Com-
parison of the results of two
questionnaire surveys in 287
pharmacists and 1216 general
practitioners by chi-square anal-
ysis. N = number of responding
pharmacists and general practi-
tioners. P-value: chi-square
analysis of differences between
the responses of pharmacists and
general practitioners who
expected that the content is
essential
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14% of them. This override is comparable with the 22% of
physicians who admitted to ignoring alerts without consid-
ering more information on the drug interaction [28]. With
respect to other studies revealing that physicians and
pharmacists override the majority of electronic alerts in
primary care [29, 30], this rate seems small. A major reason
for ignoring such alerts may be that too many alerts which
are considered irrelevant are provided [31, 32]. Conse-
quently, electronic drug-interaction systems can be config-
ured to flag only “severe” potential drug interactions. Such
a configuration was used by 18.5% of responding pharma-
cists. As expected, in these pharmacies the preoccupation
with drug interactions was reduced, drug interactions were
more frequently evaluated further, and the pharmacists
acknowledged that their electronic drug-interaction system
may be less “sensitive” while being more “specific”.
The approach to filtering potential drug interactions by
computer systems is indispensable, and a promising way to
reduce the overwhelming percentage of meaningless alerts.
Indeed, Bergk and co-workers [12] showed that their
incidence could be reduced by 28% when filtering the
percentage of minor and unspecified potential drug inter-
actions. However, the resulting prescription quality strongly
depends on the classification of the severity of potential
drug interactions, and still ignores patient characteristics
which could render a “minor” interaction “severe” for an
individual patient. Moreover, the very high number of 60%
“false” alerts (e.g. multiple or repeated alerts for the same
patient, where the patient was no longer taking the inter-
acting drug) reported in our survey indicates that the
timing of drug therapy also needs to be considered by the
interaction software in more detail. Moreover, because
many drug interactions are concentration-dependent, and
can be avoided by appropriately adjusting doses [12],
optimized drug-interaction systems should also include an
alert suppression if an interacting combination is prescribed
in adjusted doses. Hence, more sophisticated filters instead
of unjustified filters to flag only potential drug interaction
of highest severity are needed. Indeed, Peng and co-
workers [33] reported that sophisticated filters (assessment
of overlapping time of drug therapies, of duration of drug
therapy, and of total drug dose) could reduce the incidence
of potential drug-interaction alerts by 71% and—in
combination with clinical pharmacists’ review—even by
94%. Consequently, software providers should be chal-
lenged to revise and optimise the current drug-interaction
surveillance software, and also include an alerting history in
their software, because many alerts are caused by already-
checked repeat prescriptions, and therefore are probably
overridden [29, 30, 34].
Pharmacists most frequently sought information on drug
interactions in their electronic surveillance system, even
though it did not meet their expectations in most important
aspects. In paticular, most pharmacists complained about a
lack of information about non-interacting alternative ther-
apies and the specific advice for dose adjustment. General
practitioners expressed the same criticism [16]. In agree-
ment, Hansten et al. [27, 31] noticed that management
guidelines provided by drug interaction information sources
are often inadequate, and should be considered in the
classification of potential drug interactions.
With regard to the content of future drug-interaction
information sources, community pharmacists and general
practitioners expressed very different expectations, with the
Fig. 3 Reasons to contact a
physician as indicated by 287
Swiss pharmacists in a ques-
tionnaire survey
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largest difference seen in the evaluation of information
components on advice for dose adjustment and non-
interacting alternatives, which were less essential for
community pharmacists. This result reflects the different
situations and needs of the two professions in daily
practice.
In comparison with further reasons to contact a physi-
cian, potential drug interactions play an inferior role
(Fig. 2). The relatively low frequency of contacts (one per
month), with respect to the high frequency of alerts and the
statement that the majority of their patients are informed
about the detected drug interactions, indicates that, in the
process of prescribing and dispensing, community pharma-
cies mainly manage drug interaction alerts themselves. This
raises the question of the relevance and quality of this
management.
Some limitations of this survey merit discussion. First,
the overall response rate was only 57.4%, making a non-
response bias possible. However, this figure compares well
with a recent survey of German general practitioners [16]
and the fact that non-responding pharmacists did not differ
from responders suggests that such a bias will not be
critical. Second, our study was conducted in the German-
speaking part of Switzerland, and represents the health care
situation in this region in the year 2005. However, there are
many reasons justifying extrapolation of its results to other
European health care systems. Indeed, drug-interaction
software in community pharmacies from all German
speaking countries (Switzerland, Germany, and Austria) is
based on the same drug-interaction database, and in these
countries many of the software systems used by the
physicians have also integrated this database. Because of
the numerous similarities in drug prescription and dispens-
ing in Switzerland and Germany, it appears likely that the
differences observed between the two professions rather
relate to differences in their tasks and needs than differ-
ences between countries. It therefore supports the notion
that specific tools should be developed for each profession.
In conclusion, our study revealed that the drug-interac-
tion software supporting community pharmacists lacks
sensitivity and specificity, while producing a high rate of
“false” alerts. The study also showed that the information
needs of community pharmacies differed considerably from
those of general practitioners. Hence, substantial improve-
ment of drug-interaction software systems is required in
two at least important aspects—the suppression of inap-
propriate alerts and the tailoring to the needs of the user.
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